INCY

Business Context and Reporting Period

Company: Incyte Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2006
Business Overview: Incyte is a biopharmaceutical company focused on the discovery and development of novel drugs for inflammation, oncology, and HIV. The company operates as a single segment: drug discovery and development.

Key Financial Metrics

Note: Total Debt includes $91.8M current and $256.8M long-term convertible subordinated notes.

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 122% to $6.5 million, driven primarily by $5.5 million in contract revenues from a new collaboration with Pfizer. License and royalty revenues declined to $0.9 million from $2.9 million as the company discontinued its information products business.
• Improved Net Loss: Net loss narrowed by approximately $2.8 million to $17.3 million. This improvement was largely due to a $5.5 million realized gain on the sale of a portion of a publicly-held investment and increased interest income.
• Operating Expenses: Research and development (R&D) expenses increased 39% to $24.8 million. This increase included $1.4 million in contract termination costs for the discontinued DFC program and $2.3 million in stock-based compensation expense resulting from the adoption of SFAS 123R.
• Cash Flow Reversal: Operating cash flow swung from a use of $26.3 million in Q1 2005 to a provision of $15.6 million in Q1 2006, primarily due to the receipt of a $40.0 million upfront payment from Pfizer.

Guidance, Outlook, and Risks

Management Commentary and Outlook

• Pfizer Collaboration: In January 2006, Incyte entered a collaborative research and license agreement with Pfizer for CCR2 antagonist compounds. Incyte received a $40.0 million upfront payment and a $10.0 million convertible note. Future milestone payments could total up to $743.0 million.
• Program Discontinuation: In April 2006, Incyte announced the discontinuation of its most advanced clinical candidate, dexelvucitabine (DFC), due to safety concerns (grade 4 hyperlipasemia).
• Future Programs: The company is advancing a sheddase inhibitor (Phase Ib/IIa), a CCR5 antagonist (expected Phase I in Q2 2006), and a 11bHSD1 inhibitor for Type 2 diabetes (expected Phase I in Q2 2006).
• Liquidity: Management believes cash and marketable securities ($372.4 million total) are sufficient to fund operations for at least the next 12 months.

Risks and Contingencies

• Accounting Changes: Adoption of SFAS 123R on January 1, 2006, resulted in the recognition of $2.3 million in stock compensation expense, which will increase future operating expenses.
• Litigation: Ongoing patent infringement litigation with Invitrogen Corporation. The stay on proceedings was lifted in January 2006; potential damages are currently indeterminable.
• Debt Obligations: Significant debt service obligations exist, including $91.6 million of 5.5% notes due in 2007 and $250.0 million of 3.5% notes due in 2011.

Investor Verification Checklist

• Pfizer Agreement Terms: Verify the specific milestones and royalty rates associated with the $743 million potential future payments from Pfizer.
• DFC Termination Costs: Confirm the total financial impact of discontinuing the DFC program, including the $1.4 million recorded expense and any remaining liabilities.
• Debt Maturity Profile: Assess the company's ability to service or refinance the $91.6 million in 5.5% notes maturing in 2007 given the current stockholders' deficit.
• Invitrogen Litigation: Monitor the status of the patent infringement suit, as a negative outcome could result in substantial damages or injunctions.
• Stock Compensation Impact: Review the long-term impact of SFAS 123R adoption on future quarterly operating expenses and net loss.